Human NR1H4 Stable Cell Line - Hep G2

The NR1H4 gene encodes the farnesol X receptor (FXR), a member of the nuclear receptor superfamily and a major sensor and regulator of intracellular bile acid homeostasis. FXR is primarily expressed in the liver, intestine, and kidneys. After binding to primary bile acids (such as chenodeoxycholic acid), FXR translocates to the nucleus and regulates the transcription of multiple genes involved in bile acid synthesis (e.g., inhibition of CYP7A1), transport (e.g., induction of BSEP), and detoxification. In addition to its role in bile acid metabolism, FXR is a key regulator of glucose and lipid homeostasis, as well as inflammation and tissue repair. Clinically, loss-of-function mutations in NR1H4 are associated with progressive familial intrahepatic cholestasis 5 (PFIC5), a severe and often fatal neonatal liver disease. FXR is also a major therapeutic target for metabolic diseases. Dysfunction-associated steatohepatitis (MASH/NASH) and primary biliary cholangitis (PBC) are both associated with FXR. In oncology, FXR functions as a metabolic tumor suppressor; its downregulation is commonly seen in hepatocellular carcinoma and colorectal cancer.

A stable human NR1H4 cell line in the Hep G2 context is the preferred model for studying hepatic bile acid signaling, metabolic regulation, and drug-induced hepatotoxicity. Hep G2 cells retain human-specific liver characteristics and are the gold standard platform for pharmacological and toxicological studies. This cell line provides a stable platform for human NR1H4 expression, enabling researchers to reconstruct the functional FXR signaling pathway and accurately measure bile acid-dependent gene networks. This product is crucial for the pharmaceutical industry, enabling high-throughput screening of FXR agonists and assessment of the metabolic safety of candidate drugs that may interfere with bile transport. The stability of this cell line ensures the consistency and reproducibility of results from long-term exposure trials and complex metabolic profiling analyses, providing critical data for developing new therapies for cholestatic liver disease and systemic metabolic syndrome.